John Libbey Eurotext

European Journal of Dermatology


Tolerance of methotrexate in a daily practice cohort of adults with atopic dermatitis Volume 28, numéro 2, March-April 2018


1 Allergy and Clinical Immunology Department, University Hospital Lyon Sud, Pierre Bénite, France
2 CIRI (International Centre for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, 21 Avenue Tony Garnier, 69007 Lyon, France

Despite the increasing incidence of atopic dermatitis (AD), systemic treatments are still limited. Oral cyclosporine A (CsA) is the only approved drug for patients with moderate-to-severe AD failing to respond to topical agents. However, its use is limited by toxicity, which hampers the long-term management of AD. Methotrexate (MTX) could be a valuable alternative, with its well-known use by dermatologists, limited cost, and good safety profile in patients with psoriasis [1]. Having previously shown [...]